Impact of intra and postoperative oral erythromycin on gastric tube motility in patients undergoing esophageal resection.

A randomized trial of the impact of intra and postoperative oral erythromycin on gastric tube motility in patients undergoing esophageal resection.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/11/003152

Enrollment

Registered

2012-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Delayed gastric emptying after esophagectomy

Interventions

Intervention1: Erythromycin: Enteral erythromycin (250 mg, 6 hourly) intraoperatively (through a nasogastric tube) and postoperatively (initially through a nasojejunal or jejunostomy tube, and later p

Eligibility

Inclusion criteria

Inclusion criteria: 1.Proven histological diagnosis of esophageal cancer 2.ECOG performance status 0,1 3.Cardiopulmonary reserve adequate for esophageal surgery 4.American Society of Anaesthesiologists (ASA) grade I or II 5.Treatment plan of total esophageal resection 6.Esophageal substitution by stomach tube 7.Posterior mediastinal route of reconstruction 8.Patient available for follow up

Exclusion criteria

Exclusion criteria: 1.Patients with a known allergy to erythromycin or other macrolides 2.Pyloric drainage procedure performed 3.Colonic reconstruction 4.Pregnant women 5.Patients on prokinetic drugs, astemizole, terfenadine and pimozide

Design outcomes

Primary

Measure	Time frame
Short term gastric motilityTimepoint: 2 weeks	—

Secondary

Measure	Time frame
1.Medium term gastric motility 2.Toxicity Timepoint: Six months	—

Countries

India

Contacts

Public ContactDr C S Pramesh

cspramesh@gmail.com022-24177070

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026